Changes ahead for the national screening system
Changes ahead for the national screening system
Details of changes to the national screening system from 1 October, due to the closure of Public Health England.
Details of changes to the national screening system from 1 October, due to the closure of Public Health England.
We have published the annual data report for the NHS Sickle Cell and Thalassaemia (SCT) Screening Programme covering 1 April 2015 to 31 March 2016.
Well over 100 people involved in abdominal aortic aneurysm (AAA) screening throughout the UK took part in a national research day in Leicester.
Over the past few months, the NHS Sickle Cell and Thalassaemia (SCT) Screening Programme has consulted widely with colleagues from a range of services, including midwifery, specialist nurses and clinicians, screening laboratories, and patient organisations to help us revise and …
In this blog article, antenatal and newborn screening coordinator Louise Frost explains how the creation of an antenatal booking centre (ABC) improved early access and continuity of care for women at Princess Royal University Hospital (PRUH) in south east London.
As you know, e-learning for screening is changing. We have asked you to complete any outstanding e-learning modules on the CPD Screening website by 17 March.
We’re pleased to announce the publication of an updated version of the newborn laboratory handbook for the NHS Sickle Cell and Thalassaemia (SCT) Screening Programme.
The NHS Diabetic Eye Screening Programme is again joining forces with the Royal Society of Medicine (RSM) in April to hold the fourth national diabetic eye screening conference.
Today we published the key performance indicator (KPI) data for the second quarter of 2016 to 2017 (Q2, July to September 2016). The KPIs are used to measure how the NHS screening programmes are performing and aim to give a …
In 2002, I started work as Project Manager on the Sloane Project, an audit of screen-detected non-invasive carcinoma – including Ductal Carcinoma In Situ (DCIS) and Lobular Carcinoma In Situ (LCIS) – and atypical hyperplasia of the breast.